Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Australian Clinical Labs Ltd ( (AU:ACL) ) has issued an update.
Australian Clinical Labs Limited has released several documents related to its 2025 Annual General Meeting, including the AGM Notice of Meeting, Proxy Form, Shareholder Question Form, and an Online Guide from Link Market Services. The company also published its 2025 Annual Report, which includes the Corporate Governance Statement. This release indicates ACL’s commitment to transparency and adherence to corporate governance standards, potentially strengthening its position within the pathology services industry and providing stakeholders with confidence in its operational integrity.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited (ACL) is a leading Australian private provider of pathology services. Their NATA accredited laboratories conduct a wide range of pathology tests for various clients, including doctors, specialists, patients, hospitals, and corporate clients. ACL is recognized as one of the largest private hospital pathology businesses in Australia, focusing on combining talented personnel with medical and scientific leadership to enhance decision-making that improves patient outcomes.
Average Trading Volume: 909,315
Technical Sentiment Signal: Sell
Current Market Cap: A$489.5M
For an in-depth examination of ACL stock, go to TipRanks’ Overview page.